Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth.
The proapoptotic death receptor DR5 has been studied extensively in cancer cells, but its action in the tumor microenvironment is not well defined. Here, we uncover a role for DR5 signaling in tumor endothelial cells (ECs). We detected DR5 expression in ECs within tumors but not normal tissues. Treatment of tumor-bearing mice with an oligomeric form of the DR5 ligand Apo2L/TRAIL induced apoptosis in tumor ECs, collapsing blood vessels and reducing tumor growth: Vascular disruption and antitumor activity required DR5 expression on tumor ECs but not malignant cells. These results establish a therapeutic paradigm for proapoptotic receptor agonists as selective tumor vascular disruption agents, providing an alternative, perhaps complementary, strategy to their use as activators of apoptosis in malignant cells.
Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080, USA.
Nicholas S
NS
Wilson
Annie
A
Yang
Becky
B
Yang
Suzana
S
Couto
Howard
H
Stern
Alvin
A
Gogineni
Robert
R
Pitti
Scot
S
Marsters
Robby M
RM
Weimer
Mallika
M
Singh
Avi
A
Ashkenazi
D000818:Animals; D017209:Apoptosis; D002455:Cell Division; D004730:Endothelium, Vascular / Q000378:metabolism*; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000098:blood supply* / Q000473:pathology; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*
D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand